Macroglobulinemia of Waldenstrom is a cancer of the B lymphocytes (a type of white blood cell). It is associated with the overproduction of proteins called IgM antibodies.
Alternative NamesWaldenstrom's macroglobulinemia; Macroglobulinemia - primary; Lymphoplasmacytic lymphoma
Causes, incidence, and risk factorsWaldenstrom's macroglobulinemia is a result of a condition called lymphoplasmacytic lymphoma. The cause of the overproduction of the IgM antibody is unknown, but researchers believe it is made by lymphoma cells.
Overproduction of IgM causes the blood to become too thick. This is called hyperviscosity. It occasionally makes it harder for blood to flow through small blood vessels.
About 1,500 people in the United States are diagnosed with Waldenstrom's macroglobulinemia every year. Most people with this condition are over age 65, however, it may occur in younger people.
SymptomsAdditional symptoms that may be associated with this disease:
Signs and testsA physical examination may reveal a swollen spleen, liver, and lymph nodes. An eye exam may show enlarged veins in the retina or retinal bleeding (hemorrhages).
A CBC shows a low number of red blood cells and platelets. A blood chemistry shows evidence of kidney disease. A serum viscosity test can tell if the blood has become thick. Symptoms usually occur when the blood is four times thicker than normal.
A test called serum protein electrophoresis shows an increased amount of the IgM antibody. Levels seen in Waldenstrom's macroglobulinemia are generally greater than 3 g/dL.
Bone lesions are very rare. If they are present, a bone marrow examinationwill show cells that resemble both lymphocytes and plasma cells.
Additional tests that may be done:
Plasmapheresis removes unwanted substances from the blood. In macroglobulinemia, it removes or reduces the high level of IgM, and is used to quickly control the symptoms caused by blood thickening.
Drug therapy may include steroids, Leukeran, Alkeran, Cytoxan, fludarabine, or rituximab, or combinations of chemotherapy drugs.
Patients who have a low number of red or white blood cells or platelets may need transfusions or antibiotics.
Expectations (prognosis)The average survival is about 6.5 years. Some people live more than 10 years.
In some people, the disorder may produce few symptoms and progress slowly.
ComplicationsCall your health care provider if symptoms of this disorder develop.
ReferencesTreon SP, Hatjiharissi E, Leleu X, Roccaro A, Merlini G. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. In: Hoffman R, Benz EJ, Shattil SS, et al, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008:chap 88.
Rajkumar SV, Kyle RA. Plasma cell disorders. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 198.
There is no known prevention for WM
It was first identified in 1944, by the Swedish physician Jan Gosta Waldenstrom
There also is no generally-accepted course of treatment for WM.
It is estimated that it may affect about five out of every 100,000 people
Many individuals with WM have no symptoms of the disease. This is known as asymptomatic macroglobulinemia. When symptoms of WM are present, they may vary greatly
WM most often affects males over the age of 65
Other names that are sometimes used for WM include: lymphoplasmacytic lymphoma, lymphoplasmacytic leukemia,
This isnt a meaningful question you might as well ask red or white?
All lymphomas other than Hodgkin's disease, including WM, are known collectively as non-Hodgkin's lymphomas.
Jack Gelber died on May 9, 2003, in New York City, New York, USA of Waldenstrom's macroglobulinemia.
Biological therapy or immunotherapy, with the potent, immune system protein interferon alpha, is used to relieve the symptoms of WM.
Since many individuals with WM have no symptoms, the initial diagnosis may result from blood tests that are performed for some other purpose.